---

Market Overview

---

The market for cervical cancer therapeutics achieved a valuation of USD 5.5 billion in 2021 and is projected to reach USD 7.1 billion by 2027, with a compound annual growth rate (CAGR) of 4.14% during the period from 2021 to 2027. Cervical cancer is characterized by the development of malignant cells in the cervix, which is the lower part of the uterus connecting to the vagina. The primary risk factor for cervical cancer is infection with human papillomavirus (HPV).

Research estimates indicate that China had the highest number of diagnosed incident cases of cervical cancer in 2020, followed by the United States and Japan. The increasing prevalence of HIV in women is contributing to the growth of the cervical cancer drugs market. Women who are HIV positive face a higher risk of developing cervical cancer compared to the general population. Globally, around 18 million women have tested positive for HIV, and HIV weakens the immune system, thereby increasing the chances of cervical cancer. For early-stage cervical cancer, surgery is the standard treatment, while chemoradiation is commonly used for locally advanced disease. In the United States, the approvals of Keytruda as a first-line therapy and Tivdak as a second-line therapy in 2021 have significantly affected the treatment approach for recurrent and distally metastatic disease. Prior to Keytruda’s approval as a first-line therapy, patients typically received chemotherapy with Avastin, which remains the preferred treatment outside the United States.

Early detection of cervical cancer plays a crucial role, as over 90% of cases are attributed to HPV infection. Screening through Pap smear tests is the most effective method for early diagnosis of HPV and is a significant revenue-driving segment.

The market study has witnessed substantial growth due to the increasing prevalence of cervical cancer among women worldwide. In 2018, approximately 570,000 women were diagnosed with cervical cancer globally, and around 311,000 women died due to improper detection at early stages of the disease.

The introduction of novel biologic therapeutics has made a significant impact. The U.S. Food and Drug Administration (FDA) has approved biologics such as Keytruda in 2018 and 2021, as well as Tivdak in 2021, for the treatment of cervical cancer. These approved biological therapies, along with the increasing adoption of cell-based therapies, are expected to drive significant growth in the cervical cancer therapeutics market.

---

Market Segmentation

---

The market is segmented based on various factors, including drug class, histology type, distribution channel, age group, and region.

Segmentation by Drug Class
Chemotherapy
Targeted therapy

Segmentation by Histology Type
Squamous cell carcinoma
Adenocarcinoma
Aden squamous

Segmentation by Distribution Channel
Hospital & Clinics
Retail & Specialty Pharmacies

Segmentation by Age Group
Below 29 years
30-49 years
50+ years

Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan

Drug Class: Chemotherapeutic drugs are projected to dominate the global market for cervical cancer therapeutics. However, targeted therapies are expected to be the fastest-growing segment during the forecast period. The recent approvals of biological drugs such as Keytruda (pembrolizumab) and Tivdak (tisotumab-vedotin-tftv) are anticipated to drive the growth of targeted therapies.

Histology Type: Squamous cell carcinoma is expected to hold a significant share of the global market for cervical cancer therapeutics. However, adenocarcinoma is the fastest-growing segment due to its aggressive nature.

Age Group: Women aged 50 years and above are expected to account for a significant portion of the global market for cervical cancer therapeutics. However, women between the ages of 30 and 49 years are projected to be the fastest-growing segment during the forecast period.

Distribution Type: Retail and specialty pharmacy services are expected to dominate the cervical cancer therapeutics market. Managed care organizations have reported contracting with specialty pharmacy providers for their oncology business, with a majority using a single, preferred specialty provider for limited-distribution drugs.

Geography: The United States currently leads the cervical cancer therapeutics market due to factors such as increased healthcare affordability, knowledge, awareness, and technological advancements. However, China is expected to experience rapid growth with a high compound annual growth rate (CAGR) in the cervical cancer drug market, driven by improved healthcare access and quality, increased disease management awareness, and rising healthcare expenditure. The introduction of biosimilars in emerging markets like China and Japan may also impact the therapeutic landscape in these regions.

The cervical cancer portfolio consists of over 169 assets in various stages of development. Most industry-sponsored drugs in clinical development for cervical cancer are in Phase II. Phase II accounts for the highest proportion of pipeline drugs, followed by Phase I and Phase III.

The clinical trial portfolio includes over 282 trials in different phases of development. The majority of industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with a few in the New Drug Application (NDA) or Biologics License Application (BLA) stage. Most clinical trials for cervical cancer are in the early and mid-phases of development, with only a small percentage in Phase III and IV. The United States has a significant number of cervical cancer clinical trials globally, followed by the United Kingdom in Europe and China in Asia. Promising results from pembrolizumab and the role of PD-L1 in cervical cancer have led to investigations of various anti-P.D.-(L)1 agents as first-line therapies, such as Atezolizumab and prolgolimab (BCD-100) in combination with chemotherapy, with or without bevacizumab, and pembrolizumab in combination with chemoradiotherapy. Additionally, several trials are exploring novel combinations in this field.

---

Competitive Landscape

---

The market for cervical cancer treatment is characterized by the presence of numerous companies offering both generic and patented/commercial drugs for this purpose. In 2014, the U.S. Food and Drug Administration (FDA) approved the use of bevacizumab (Avastin), an antiangiogenic agent, for the treatment of persistent, recurrent, or metastatic cervical cancer. This marked the introduction of biologics in the field of cervical cancer treatment. Avastin received approval in Europe and Japan in subsequent years, namely 2015 and 2016. Subsequently, Keytruda (pembrolizumab) was approved by the FDA in 2018, followed by Tivdak (tisotumab-vedotin-tftv) in 2021, for the treatment of cervical cancer. While generic products continue to hold a significant share of the market, the emergence of biologics and targeted therapies signifies a shift in the treatment landscape.

The cervical cancer portfolio currently comprises more than 169 assets in various stages of development, with over 40% of the pipeline specifically targeting cervical cancer. Advancements in biotherapeutics, including cell and gene therapies, antibodies, antibody-drug conjugates, and bispecific antibodies, are being increasingly employed. Novel therapeutic options such as cadonilimab, socazolimab, prolgolimab, durvalumab, ocrelizumab, serplulimab, catequentinib, among others, are emerging for the treatment of cervical cancer. The introduction of these innovative drugs will likely bring about a significant change in the approach to cervical cancer treatment. With a vast number of molecules in various stages of development, it is anticipated that new market entrants will introduce novel mechanisms of action along with improved safety and efficacy profiles compared to existing patented commercial drugs.

Prominent players operating in the cervical cancer treatment market include Regeneron Pharmaceuticals, Akesobio, AstraZeneca, Merck KGaA, Seagen Inc., Qilu Pharmaceutical Co., Ltd., Roche, Guangzhou Gloria Biosciences Co., Ltd., Lee’s Pharmaceutical, BeiGene, Helix Biotech, Biocad, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Innovent Biologics, and others. These companies are actively engaged in research and development initiatives aimed at the creation of technologically advanced and innovative cervical cancer drugs. Moreover, they are forming collaborations to maintain their market position.

Key companies profiled in this report include Seagen Inc, Merck, Roche, Pfizer, Sanofi/Regeneron, Lee’s Pharma/Sorrenti, Akesobio, HengRui Medicine Co., Ltd, Henlius Biotech, Biocad, Advenchen Laboratories, EXELIXIS, Novertis, GSK, Zeria Pharmaceuticals, Innovent Biologics, Clovis Oncology, IOVANCE Biotherapeutics, Genor Biopharma Co., LTD, Agenusbio, Qilu Pharmaceutical, Astrazeneca, Puma Biotechnology, Genmab, Takeda, Incyte Corp, BioAtla, Inc., Helsinn Healthcare SA, Qilu Pharmaceutical, BeiGene.

---

Key Questions Answered

---

WHAT IS THE MARKET SIZE OF THE CERVICAL CANCER THERAPEUTICS MARKET?

The market size of the cervical cancer therapeutics market was valued at USD 5538.71 million in 2021 and is projected to reach USD 7117.40 million by 2027.

WHAT IS THE GROWTH RATE OF THE CERVICAL CANCER THERAPEUTICS MARKET?

The cervical cancer therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 4.14% during the period of 2021-2027.

WHO ARE THE KEY PLAYERS IN THE CERVICAL CANCER THERAPEUTICS MARKET?

The key players in the cervical cancer therapeutics market include Merck & Co Inc (Merck), Seagen Inc (Seagen), F. Hoffmann-La Roche Ltd (Roche), Pfizer Inc (Pfizer), and Amgen Inc.

WHAT ARE THE SEGMENTS COVERED IN THE CERVICAL CANCER THERAPEUTICS MARKET?

The segments covered in the cervical cancer therapeutics market include drug class, histology type, distribution channel, age group, and region.